Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 in Children and Adolescents With Hyperphenylalaninemia
NCT00432822Phase 3Terminated
- Sponsor
- Orphanetics Pharma Entwicklungs
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of sapropterin in phenylketonuria (PKU), hyperphenylalaninemia (HPA), sponsored by Orphanetics Pharma Entwicklungs. Status: terminated.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)hyperphenylalaninemia (HPA)
Beyond the preview
Go deeper on NCT00432822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432822.